Diagnosing Hepatocellular Carcinoma Using Sonazoid Contrast-Enhanced Ultrasonography: 2023 Guidelines From the Korean Society of Radiology and the Korean Society of Abdominal Radiology

Sonazoid, a second-generation ultrasound contrast agent, was introduced for the diagnosis of hepatic nodules. To clarify the issues with Sonazoid contrast-enhanced ultrasonography for the diagnosis of hepatocellular carcinoma (HCC), the Korean Society of Radiology and Korean Society of Abdominal Rad...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Woo Kyoung, Kang, Hyo-Jin, Choi, Sang Hyun, Park, Mi-Suk, Yu, Mi Hye, Kim, Bohyun, You, Myung-Won, Lim, Sanghyeok, Cho, Young Seo, Lee, Min Woo, Hwang, Jeong Ah, Lee, Jae Young, Kim, Jung Hoon, Joo, Ijin, Bae, Jae Seok, Kim, So Yeon, Chung, Yong Eun, Kim, Dong Hwan, Lee, Jeong Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Radiology 2023
Materias:
Recommendation and Guideline
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248355/
https://www.ncbi.nlm.nih.gov/pubmed/37271203
http://dx.doi.org/10.3348/kjr.2023.0324
Descripción
Sumario:Sonazoid, a second-generation ultrasound contrast agent, was introduced for the diagnosis of hepatic nodules. To clarify the issues with Sonazoid contrast-enhanced ultrasonography for the diagnosis of hepatocellular carcinoma (HCC), the Korean Society of Radiology and Korean Society of Abdominal Radiology collaborated on the guidelines. The guidelines are de novo, evidence-based, and selected using an electronic voting system for consensus. These include imaging protocols, diagnostic criteria for HCC, diagnostic value for lesions that are inconclusive on other imaging results, differentiation from non-HCC malignancies, surveillance of HCC, and treatment response after locoregional and systemic treatment for HCC.

Ejemplares similares